Net sales and profits rose year-over-year, driven by Machinery and Pharmaceuticals, with extraordinary gains from asset sales. Full-year forecasts were revised upward, and a major share repurchase was completed.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.